Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 21, 2017. The report details the vesting of conditional share awards under the 2009 Deferred Annual Bonus Plan (DABP) for a Person Discharging Managerial Responsibilities (PDMR), specifically Ms. C. Thomas, SVP of Human Resources. The awards relate to a three-year performance period from January 1, 2014, to December 31, 2016.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. It focuses exclusively on executive compensation metrics and share transaction details.
- Share Price at Vesting: £16.89 (March 20, 2017).
- Total Shares Released: 3,954 Ordinary Shares (2,965 Co-investment shares and 989 Matching Award shares).
- Transaction Price: £0.00 per share (vesting of conditional awards).
- R&D New Product Sales (Performance Metric): £6.717 billion achieved against a maximum vesting threshold of £4.428 billion.
Material Changes and Performance Outcomes
The vesting outcome for the 2014 award was mixed based on three performance measures:
- Adjusted Free Cash Flow: The company did not meet the threshold level; this portion (1/3) lapsed in full (0% vesting).
- Total Shareholder Return (TSR): GSK ranked 9th out of 10 comparator companies (below median); this portion (1/3) lapsed in full (0% vesting).
- R&D New Products Sales: The company exceeded the maximum vesting level; this portion (1/3) vested in full (33.33% of total award).
- Overall Vesting: 33.33% of the total award vested, while 66.67% lapsed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future strategy, or discussion of general corporate risks. It notes that the balance of the Matching Award for the specific PDMR has lapsed. The report references adjustments made to the R&D sales measure due to the "three-part transaction with Novartis," indicating the impact of prior corporate restructuring on performance metrics.
Key Facts for Investor Verification
- Verify the specific impact of the Novartis transaction on GSK's reported R&D New Product sales figures.
- Confirm the company's TSR ranking relative to its peer group for the 2014-2016 period.
- Review the full terms of the 2009 Deferred Annual Bonus Plan to understand the threshold levels for adjusted free cash flow.
- Note that this filing is a transaction notification for a specific executive and does not reflect broader company financial performance.